Thymoquinone Nanoparticles (TQ-NPs) in Kidney Toxicity Induced by Ehrlich Ascites Carcinoma (EAC): An In Vivo Study

Overview

Journal Can J Kidney Health Dis

Publisher Sage Publications

Date 2024 Jun 12

PMID 38863503

Authors

Zakaria Eltahir

Maha Ibrahim

Muniera Y Mohieldeen

Ammar Bayoumi

Samia M Ahmed

Affiliations

Soon will be listed here.

Abstract

Background: Cisplatin (Cis) is potent chemotherapy used to treating already many different types of cancer; however, it is found to correlate with nephrotoxicity and other adverse health consequences. Thymoquinone (TQ) is an antioxidant and anti-inflammatory molecule that may defend against the consequences of different chemotherapies. Thymoquinone uses, although, are negatively impacted by its weak solubility and inadequate biological availability.

Objectives: This investigation examined the efficacy of a new nanoparticle (NP) absorbing TQ in an Ehrlich Ascites Carcinoma (EAC) mice model to address its low solubility, enhance its bioavailability, and protect against Cis-induced nephrotoxicity.

Methods: Following 4 treatment groups were included in this research: (1) control, (2) EAC, (3) EAC + Cis + Thymoquinone nanoparticle (TQ-NP) treated, and (4) EAC + Cis-treated.

Results: The study revealed that TQ-NP was efficacious in avoiding Cis-induced kidney problems in EAC mice, as well as restoring kidney function and pathology. Thymoquinone nanoparticle considerably reduced Cis-induced oxidative damage in renal tissue by augmenting antioxidant levels. According to tumor weight and histological investigation results, TQ-NP did not impair Cis's anticancer efficacy.

Conclusion: Thymoquinone nanoparticle might be used as a potential drug along with Cis anticancer therapy to reduce nephrotoxicity and other side effects while maintaining Cis anticancer properties.

References

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

Chiou Y, Jiang S, Ding Y, Cheng Y . Kidney-based in vivo model for drug-induced nephrotoxicity testing. Sci Rep. 2020; 10(1):13640. PMC: 7428004. DOI: 10.1038/s41598-020-70502-3. View

Tousson E, Hafez E, Abo Gazia M, Salem S, Mutar T . Hepatic ameliorative role of vitamin B17 against Ehrlich ascites carcinoma-induced liver toxicity. Environ Sci Pollut Res Int. 2020; 27(9):9236-9246. DOI: 10.1007/s11356-019-06528-6. View

Farooqui Z, Shahid F, Khan A, Khan F . Oral administration of Nigella sativa oil and thymoquinone attenuates long term cisplatin treatment induced toxicity and oxidative damage in rat kidney. Biomed Pharmacother. 2017; 96:912-923. DOI: 10.1016/j.biopha.2017.12.007. View

Desoize B, Madoulet C . Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 2002; 42(3):317-25. DOI: 10.1016/s1040-8428(01)00219-0. View

Elmowafy M, Samy A, Raslan M, Salama A, Said R, Abdelaziz A . Enhancement of Bioavailability and Pharmacodynamic Effects of Thymoquinone Via Nanostructured Lipid Carrier (NLC) Formulation. AAPS PharmSciTech. 2015; 17(3):663-72. DOI: 10.1208/s12249-015-0391-0. View

Panesso M, Shi M, Cho H, Paek J, Ye J, Moe O . Klotho has dual protective effects on cisplatin-induced acute kidney injury. Kidney Int. 2013; 85(4):855-70. PMC: 3972320. DOI: 10.1038/ki.2013.489. View

Donia T, Gerges M, Mohamed T . Amelioration effect of Egyptian sweet orange hesperidin on Ehrlich ascites carcinoma (EAC) bearing mice. Chem Biol Interact. 2018; 285:76-84. DOI: 10.1016/j.cbi.2018.02.029. View

Trang N, Wanner M, Phuong L, Koomen G, Dung N . Thymoquinone from Eupatorium ayapana. Planta Med. 1993; 59(1):99. DOI: 10.1055/s-2006-959619. View

10.

Saghir S, Al-Gabri N, Khafaga A, El-Shaer N, Alhumaidh K, Elsadek M . Thymoquinone-PLGA-PVA Nanoparticles Ameliorate Bleomycin-Induced Pulmonary Fibrosis in Rats via Regulation of Inflammatory Cytokines and iNOS Signaling. Animals (Basel). 2019; 9(11). PMC: 6912694. DOI: 10.3390/ani9110951. View

11.

Hajhashemi V, Ghannadi A, Jafarabadi H . Black cumin seed essential oil, as a potent analgesic and antiinflammatory drug. Phytother Res. 2004; 18(3):195-9. DOI: 10.1002/ptr.1390. View

12.

Mahmoud Y, Abdelrazek H . Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy. Biomed Pharmacother. 2019; 115:108783. DOI: 10.1016/j.biopha.2019.108783. View

13.

Badary O, Nagi M, Al-Shabanah O, Al-Sawaf H, Al-Sohaibani M, Al-Bekairi A . Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. Can J Physiol Pharmacol. 1998; 75(12):1356-61. View

14.

Shoieb A, Elgayyar M, Dudrick P, Bell J, Tithof P . In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int J Oncol. 2002; 22(1):107-13. View

15.

Nessa M, Beale P, Chan C, Yu J, Huq F . Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models. Anticancer Res. 2011; 31(11):3789-97. View

16.

. UKCCCR guidelines for the use of cell lines in cancer research. Br J Cancer. 2000; 82(9):1495-509. PMC: 2363383. DOI: 10.1054/bjoc.1999.1169. View

17.

Leibbrandt M, Wolfgang G, Metz A, Ozobia A, Haskins J . Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int. 1995; 48(3):761-70. DOI: 10.1038/ki.1995.348. View

18.

Ganea G, O Fakayode S, Losso J, van Nostrum C, Sabliov C, Warner I . Delivery of phytochemical thymoquinone using molecular micelle modified poly(D, L lactide-co-glycolide) (PLGA) nanoparticles. Nanotechnology. 2010; 21(28):285104. DOI: 10.1088/0957-4484/21/28/285104. View

19.

Abd Eldaim M, Tousson E, Sayed I, Abd Elmaksoud A, Ahmed A . Ameliorative effects of 9-diaminoacridine derivative against Ehrlich ascites carcinoma-induced hepatorenal injury in mice. Environ Sci Pollut Res Int. 2021; 28(17):21835-21850. DOI: 10.1007/s11356-020-11857-y. View

20.

Fayi M, Otifi H, Alshyarba M, Dera A, Rajagopalan P . Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NFκB, KIM-1 and ameliorating Nrf2/HO-1 signalling. J Drug Target. 2020; 28(9):913-922. DOI: 10.1080/1061186X.2020.1722136. View